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Abstract
Background: The placement of prophylactic intra-abdominal drains has been common practice in abdominal
operations including pancreatic surgery. The PANDRA trial showed that the omission of drains following pancreatic
head resection was non-inferior to intra-abdominal drainage in terms of postoperative reinterventions and superior
in terms of clinically relevant pancreatic fistula rate and fistula-associated complications. The aim of the present
PANDRA II trial is to evaluate the clinical outcome with versus without prophylactic drain placement after distal
pancreatectomy.
Methods: The PANDRA II trial is a mono-center, randomized controlled, non-inferiority trial with two parallel study
groups. In the control group at least one passive intra-abdominal drain is placed at the pancreatic resection margin. In
the experimental group no drains are placed. The primary endpoint of this trial will be the Comprehensive Complication
Index (CCI) measuring all postoperative complications within 90 days. Secondary endpoints are in-hospital mortality and
morbidity, including the rates of postoperative pancreatic fistula, chyle leak, postpancreatectomy hemorrhage, delayed
gastric emptying, reinterventions and reoperations, surgical site infection, and abdominal fascia dehiscence. Moreover,
length of hospital stay, duration of intensive care unit stay, and the rate of readmission after discharge from hospital
(up to day 90 after surgery) are assessed. We will need to analyze 252 patients to test the hypothesis that no
drainage is non-inferior to drain placement in terms of the CCI (δ 7.5 points) in a one-sided t test with a one-
sided level of significance of 2.5% and a power of 80%.
Discussion: The results of the PANDRA II trial will help to evaluate the effect of an omission of prophylactic
intraperitoneal drainage on the rate of complications after open or minimally invasive distal pancreatectomy.
Trial registration: German Clinical Trials Register (DRKS), DRKS00013763. Registered on 6 March 2018.
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Background
The placement of prophylactic intra-abdominal drains to
reduce postoperative surgical complications has been
common practice in abdominal surgery for decades.
Recent studies, however, have failed to show any benefit
of routine drainage following many abdominal resections
including hepatobiliary [1, 2], gastric [3, 4], and colorec-
tal surgery [5, 6]. These studies have shown that surgery
can be performed safely without prophylactic drainage.
Although the use of prophylactic drains was shown to
be unnecessary in other resections, many surgeons fear
that abandoning prophylactic drainage after a pancreatic
resection could be detrimental due to the high rate and
severe consequences of pancreatic fistula. While mor-
tality after pancreatic resections has been significantly
reduced, postoperative morbidity following pancreatic
surgery remains a concern and is as high as 40–50%
even in specialized centers [7–9]. For many surgeons the
rationale for inserting drains following pancreatic sur-
gery is to evacuate the blood, bile, pancreatic juice, or
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chyle that may accumulate after pancreatic surgery, which
can serve as an early warning sign of postoperative
pancreatic fistula and its associated complications such as
postpancreatic hemorrhage. However, the majority of
patients do not develop postoperative pancreatic fistula,
and experiences with drains in other operations [1–6]
suggest that unnecessary drains can cause complications.
Drains might serve as a port of entry for bacteria and turn
non-infected postoperative fluid collections into abscesses
and infected fistula. In addition, drains might cause tissue
trauma from suction, erode anastomoses, and cause intes-
tinal leaks [10]. Several randomized and non-randomized
trials have attempted to identify risk constellations where
placement of abdominal drains after pancreatic surgery
seems to be justified [7, 10–13]. Other studies have tried
to explore the effectiveness of early versus late removal of
abdominal drains [14, 15]. In 2017, the PANDRA trial
showed that the omission of drains following pancreatic
head resection was non-inferior to intra-abdominal drain-
age in terms of postoperative reinterventions and superior
in terms of clinically relevant pancreatic fistula rate and
fistula-associated complications [16]. Therefore, some
surgeons have abandoned the routine use of drains in pan-
creatic surgery. Nonetheless, most pancreatic surgeons
continue to use a prophylactic drain. Up to now it is
unclear whether routine abdominal drainage after distal
pancreatectomy has any effect on the reduction of post-
operative complications. The aim of the present PANDRA
II trial is to evaluate the clinical outcome of prophylactic
drain placement versus no drainage after open or mini-
mally invasive distal pancreatectomy with respect to post-
operative complications.
Study design
Objectives and hypotheses
The PANDRA II trial investigates differences in the post-
operative course after distal pancreatectomy comparing
the surgical technique with placement of an abdominal
drain versus no placement of an abdominal drain after
open or minimally invasive distal pancreatectomy.
The following hypotheses will be tested:
H0: The risk of developing postoperative complications
is different between the two groups.
H1: The risk of developing postoperative complications
is equal in both groups.
Study registration, ethics, and consent
Before inclusion of the first patient, the trial protocol
was approved by the ethics committee of the University
of Heidelberg (Ethikkommission Medizinische Fakultät
Heidelberg, S-675/2017) and the trial was registered
(DRKS00013763; UTN: U1111-1207-3031). The trial will
be conducted at the Clinical Trial Center (KSC) of the
Department of General, Visceral and Transplantation Sur-
gery, University Hospital Heidelberg in the context of
Good Clinical Practice and in accordance with the Decla-
ration of Helsinki. Randomization and data management
are performed by the KSC. The statistical analysis will be
performed independently by the Institute of Medical
Biometry and Informatics (IMBI) of the University of
Heidelberg. The PANDRA II trial is designed as a mono-
center, randomized controlled, non-inferiority trial with
two parallel study groups. All patient-related information
is subject to medical confidentiality and to medical secrecy
according to the European General Data Protection Regu-
lation (DSGVO — Datenschutzgrundverordnung), the
Federal Data Protection Act (Bundesdatenschutzgesetz),
and the State Data Protection Act (Landesdatenschutzge-
setz). Third parties will not have any insight into ori-
ginal data.
Study population
All patients assigned for distal pancreatectomy at the
Department of General, Visceral and Transplantation
Surgery, University of Heidelberg, will be screened for
eligibility before the operation. Eligible for participation
are all patients planned for open or minimally invasive
distal pancreatectomy for pancreatic disease. Patients
must be at least 18 years of age and provide written
informed consent. Patients have to be able to understand
character and individual consequences of the clinical trial.
The following exclusion criteria have been defined: (1) in-
dication for pancreatic resection with a pancreaticojejunal
anastomosis, (2) American Society of Anesthesiologists
(ASA) physical status classification ≥4, (3) impaired men-
tal state or language barriers impeding informed consent,
(4) participation in another interventional trial with inter-
ference of intervention and outcome of this trial (Table 1).
During this preoperative visit, patients will be informed
about the clinical problem of postoperative complications,
the timeline of the PANDRA II trial, and the possible risks
and benefits of participation before they will be asked to
give their written informed consent.
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
• Surgical indication for open
or minimally invasive distal
pancreatectomy
• Aged 18 years and over
• Ability of subject to understand
character and individual
consequences of the clinical trial
• Informed consent provided
• The subject has a surgical
indication for pancreatic
resection with a
pancreaticojejunal anastomosis
• American Society of
Anesthesiologists (ASA) physical
status classification ≥ IV
• Impaired mental state or
language problems of the subject
• Participation in another
interventional trial with
interference of intervention
and outcome of this trial
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Outcome parameters
Overall postoperative morbidity assessed with the Com-
prehensive Complication Index (CCI) [17] was chosen as
primary endpoint since this parameter considers the
patient’s perspective as well as parameters of surgical
effectiveness. A score of 0 indicates no complications,
whereas 100 is equivalent to death. The index is based on
the established Clavien-Dindo classification [18]. The score
is validated for the pancreatic surgical population, and a
difference of 10 is regarded as a clinically relevant dif-
ference [17]. An endpoint reflecting the entire spectrum of
complications like the CCI is highly appropriate to
compare two different surgical strategies for the abdominal
cavity. The score will be calculated respecting all compli-
cations within 3months after the index operation.
Secondary endpoints are in-hospital mortality and
also postoperative morbidity up to day 90 after the
index surgery, including frequency of postoperative
pancreatic fistula according to the definition of the
International Study Group of Pancreatic Surgery (ISGPS)
2017 [19]; lymphatic fistula according to the definition of
the ISGPS 2017 [20]; postoperative bleeding accor-
ding to the definition of the ISGPS 2007 [21]; re-
interventions and reoperations including computed
tomography (CT)-guided placement of drains due to
intra-abdominal fluid collection, intra-abdominal bleed-
ing, and/or pancreatic and lymphatic fistula; delayed
gastric emptying according to the 2007 ISGPS de-
finition [22]; surgical site infection according to
Centers for Disease Control and Prevention (CDC)
definition; and abdominal fascia dehiscence. More-
over, operation time and length of hospital stay,
duration of ICU stay, as well as the rate of readmis-
sion after discharge from hospital (up to day 90 after
surgery) are assessed.
Randomization
All participating patients are randomized intraopera-
tively once the surgical decision to perform a distal
pancreatectomy has been made by the attending
surgeon. The randomization will be performed prior to
pancreatic resection. Block randomization with varying
block sizes is performed with a 1:1 allocation ratio. A
computer generated random list was created. The allo-
cation is performed by opening sequentially numbered
opaque envelopes containing a card marked “Drainage”
or “No Drainage”. The randomization process and
assignment of the patients to the respective trial inter-
vention are performed by staff members of the KSC at
the University Hospital Heidelberg. If the surgical pro-
cedure of a distal pancreatectomy is not accomplished
after randomization, e.g., due to inoperability or the
need for total pancreatectomy, the patient is excluded
from final analysis.
Standardized surgical approach
For both groups
Open or minimally invasive distal pancreatectomy is
performed by the surgeon according to local practice.
Conversion from laparoscopic to open resection will be
documented in the case report form, but does not lead
to exclusion of a patient. Additional partial resection of
larger veins or arteries (e.g., the superior mesenteric/por-
tal vein or celiac trunk) is allowed. Furthermore, patients
with additional resection of other organs (e.g., colon,
liver, spleen) or even distal pancreatectomy combined
with multivisceral resection are also eligible. The deci-
sion to perform an additional splenectomy or cholecys-
tectomy is at the surgeon’s discretion. The type of
abdominal incision (longitudinal or transverse laparo-
tomy) as well as the placement of trocars in terms of
laparoscopic pancreatic resections is determined by the
surgeon performing the procedure. After exploration of
the abdominal cavity, the pancreas is revealed and trans-
ected by scalpel or by stapler as no differences in
pancreatic fistula rate have been reported between differ-
ent transection techniques. A coverage procedure with,
e.g., the falciform ligament or suturing the ventral and
dorsal surfaces of the gland by single stitches or running
suture of the pancreatic remnant is at the discretion of
the surgeon performing the procedure and will be docu-
mented. Further manipulation of the pancreatic remnant
such as the use of fibrin glue or reinforcement with
meshes is not allowed, as these methods have failed to
show any benefit [23]. The use of somatostatin and its
analogs is not standardized in the trial protocol, but it
needs to be documented and will be analyzed separately
for both groups.
Control group
In the control group at least one drain (open-circuit
silicone drain or closed-circuit silicone drain) is placed
at the pancreatic remnant for percutaneous drainage
just before abdominal wall closure. Amylase values are
measured on the third postoperative day in the drained
fluid. There is no restriction on the number of days the
drains should remain. They can be removed whenever
they are no longer needed, justified by the clinical state
of the patient.
Experimental group
In the experimental group no drains are placed.
Postoperative data collection and blinding
Postoperative data collection is performed at prespe-
cified time points. Regular visits with study patients
on all wards will be performed by clinical investi-
gators and study nurses from the clinical study center
in order to collect information on the primary and
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secondary outcome parameters and to identify any
postoperative complication. Two postoperative study visits
(3rd postoperative day and 10th postoperative day/ day of
discharge) and two follow-up telephone interviews after
discharge (30 days and 90 days postoperatively) will be
performed (Fig. 1). All surgeons must describe the tech-
nique they performed on the pancreas on a standardized
form that is sent to them by email on the day of the index
operation to record whether patients were treated accor-
ding to the study protocol and were assigned to their
groups truly at random. Blinding to the treatment al-
location for participants, research assistants, operating
surgeons, data collectors, and outcome assessors is
difficult — if not impossible — as drain placement is ob-
vious. However, the primary and secondary outcome
measures are objective endpoints that are not influenced
by blinding. Therefore, only data analysts will be blinded
in this trial.
Safety aspects
All postoperative complications are monitored during
hospital stay and follow-up examinations (up to day 90).
Major complications are defined as complications graded
IV and V according to the Clavien-Dindo classification
[18]. (The Clavien-Dindo classification grades are listed in
Additional file 2). The coordinating investigator must be
informed about these complications. Additionally, there
are evaluations of mortality after including 30 and 90
patients, respectively, into the study. If there is a signifi-
cantly increased rate of mortality in one of the groups,
there will be an early termination of the trial.
Sample size calculation
The sample size calculation is based on the primary out-
come parameter CCI [17] in a non-inferiority design.
Assumptions are made on in-house calculations of the
CCI on data from the DISPACT trial [24] and the NUR-
IMAS Pancreas study [25] (mean CCI 30; standard
deviation 20). A decrease of the CCI by 10 points is
considered relevant by patients and clinicians. Therefore,
a margin of 7.5 CCI points will be tolerated as non-
inferior. With a significance level of 2.5% and 80%
power, we need to analyze 113 patients in each group
(Nquery 7.0). With an additional dropout of 10%, 126
Fig. 1 Enrollment, interventions, and assessment schedule of the PANDRA II trial: course of examinations (modified SPIRIT figure)
Kaiser et al. Trials          (2019) 20:332 Page 4 of 7
patients need to be allocated to the no drain and drain
arms, respectively. Based on the department’s data,
recruitment will be completed within 36months after
inclusion of the first patient.
Statistical analysis
Non-inferiority of no drain versus drain after distal
pancreatectomy will be assessed using a one-sided t test.
The one-sided significance level is set to 2.5%. The
hypotheses to be assessed in the primary efficacy analysis
are as follows: H0: μNo Drainage – μDrainage ≥ δ and
H1: μNo Drainage – μDrainage < δ, where δ = 7.5 re-
presents the chosen non-inferiority margin and μNo
Drainage, μDrainage denote the mean CCI in the no
drain and drain groups, respectively. The primary effi-
cacy analysis will be based on the intention-to-treat set
according to the intention-to-treat principle. Addition-
ally, an evaluation of the primary outcome will be per-
formed in the per protocol set and in the as treated set
(where all patients will be analyzed as they were treated)
as sensitivity analyses. Missing data for the primary out-
come variable will be replaced by using multiple imput-
ation [26], which takes the covariate treatment group
into account by application of the fully conditional
specification method. All secondary outcomes will be
evaluated descriptively, and descriptive p values will be
reported together with 95% confidence intervals for the
corresponding effects. All analyses will be done using
program R 3.2 or higher. Statistical analysis will be
performed after closure of the database.
Methods for minimizing bias
Minimizing selection bias
All patients will be consecutively screened and, if found
to be eligible, will provide informed consent. The
number of screened, included, and analyzed patients will
be reported and differences will be explained. The
patient flow and the Consolidated Standards of Repor-
ting Trials (CONSORT) flowchart will be reported in
the final analysis.
Minimizing attrition bias
Statistical measurements such as imputation will be
taken to minimize risk of bias due to incomplete out-
come data. The trial is registered with the German
Clinical Trials Register (Deutsches Register Klinischer
Studien), DRKS00013763. To avoid the risk of se-
lective reporting, the trial protocol with full infor-
mation about endpoints and a profound explanation
of planned statistical analysis is hereby published
according to the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) state-
ment where appropriate [27]. The SPIRIT checklist is
provided as Additional file 1.
Discussion
Distal pancreatectomy for pancreatic diseases is the
second most common surgical procedure on the
pancreas. Despite the increasing caseload, the morbidity
associated with this kind of operation remains high, even
in specialized centers [7, 8]. Additional diagnostic and
therapeutic procedures are needed for these patients,
leading to prolongation of their hospital stay, re-
admission, and an increase in treatment costs [28].
Several randomized and non-randomized trials have
attempted to identify risk constellations where place-
ment of abdominal drains after pancreatic surgery is
justified [7, 10–13]. Other studies have tried to ex-
plore the effectiveness of early versus late removal of
abdominal drains [14, 15].
In 2001, Conlon et al. [29] published the first single-
center randomized trial on the usefulness of drains in
pancreatic surgery. This study included 139 patients
with pancreatoduodenectomy and 40 patients with distal
pancreatectomy, with 88 patients randomized to drain
and 91 to no-drain. Conlon et al. could show that there
was no difference in morbidity, reintervention, or
mortality rate. Therefore, these authors concluded that
drains should not be considered mandatory or standard
after pancreatic resection [29]. In 2011, Van Buren et al.
[30] set up a similar multicenter randomized prospective
trial to investigate the usefulness of an abdominal drain
in patients undergoing pancreatoduodenectomy as well
as distal pancreatectomy. However, in 2014 this trial had
to be terminated prematurely after 137 patients by a
Data Safety Monitoring Board decision because of a
higher mortality frequency in the no-drain group in
patients with pancreatoduodenectomy. In contrast to
Conlon et al., these researchers could show decreased
mortality and morbidity with routine drainage after
pancreatoduodenectomy [30]. In 2015, Dou et al. [31]
published a systematic review and meta-analysis of
prophylactic abdominal drainage after pancreatic re-
section to investigate whether prophylactic abdominal
drainage is necessary after pancreatic resection or not.
They included nine eligible studies involving a total of
2794 patients in this meta-analysis and showed that
placement of prophylactic drainage did not have benefi-
cial effects on clinical outcomes, including morbidity,
postoperative pancreatic fistula, reoperation, interven-
tional radiology drainage, and length of hospital stay.
Additionally, prophylactic drainage did not significantly
increase the risk of abdominal abscess. Omitting prophy-
lactic abdominal drainage resulted in higher mortality
after pancreatectomy. Therefore, Dou et al. still re-
commended prophylactic abdominal drainage after
pancreatic resection [31]. In 2016, Witzigmann et al.
could show that the omission of drains in patients with
pancreatic head resection and pancreatic anastomosis
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was not inferior to intra-abdominal drainage in terms of
postoperative reintervention and superior in terms of
clinically relevant pancreatic fistula rate and fistula-
associated complications [16]. According to Witzigmann
et al., there seems to be no need for routine prophylactic
drainage after pancreatic resection with pancreaticojeju-
nal anastomosis. In 2017, Van Buren et al. [32] published
another multicenter trial including a total of 344 patients
who underwent distal pancreatectomy with and without
the use of intraperitoneal drainage (174 versus 170
patients). In contrast to the results of 2014, Van Buren
et al. showed that there was no difference in the rate of
grade II or higher complications and also no difference
in clinically relevant postoperative pancreatic fistula or
mortality. However, distal pancreatectomy without rou-
tine intraperitoneal drainage was associated with a
higher incidence of intra-abdominal fluid collection.
Nevertheless, there was no difference in the frequency of
postoperative imaging, percutaneous drain placement,
reoperation, readmission, or quality of life scores [32]. In
2017, Huettner et al. published a meta-analysis of studies
comparing abdominal drainage with no drainage after
pancreatic surgery. They included the randomized con-
trolled trials of Conlon et al. [29], Van Buren et al. [30],
and Witzigmann et al. [32] and showed that pancreatic
resection with or without abdominal drainage resulted
in similar rates of mortality, morbidity, and reinterven-
tion [33].
Some surgeons have abandoned the routine use of
drains in pancreatic surgery, but many surgeons still fear
that abandoning prophylactic drainage after a pancreatic
resection may be hazardous and result in an increase of
potentially severe complications. On the other hand, the
possibility of drain-related morbidity needs to be consi-
dered, and routine drainage should not be accepted as a
historic standard without being allowed to challenge this.
As the above-mentioned studies on drainage practice in
pancreatic surgery show conflicting results, the scientific
discussion may not be terminated after completion of
one randomized controlled trial for a specific topic. The
ongoing intense debate on whether routine abdominal
drainage after distal pancreatectomy has any effect on
the reduction of postoperative complications shows the
need for more high-quality studies. Consequently, the
present single-center PANDRA II trial will provide
additional evidence for the question of routine drain
placement in distal pancreatectomy and will increase the
available evidence in this field in addition to the already-
published studies. The aim of the present single-center
RCT is to evaluate the outcome after open or minimally
invasive pancreatic distal pancreatectomies concerning
the presence or absence of prophylactic abdominal cavity
drainage. Specific outcome endpoints are postoperative
complications.
Trial status
The PANDRA II trial recruitment started in April 2018
and is currently ongoing. The last patient is expected to
be recruited early in 2021.
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
Additional file 2: Classification of surgical complications according to
Clavien-Dindo [18]. (DOCX 14 kb)
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